Melane Sampson, Author at BioTuesdays

Developments

atai Life Sciences prices $225-million IPO

atai Life Sciences (NASDAQ:ATAI) priced an initial public offering of 15 million common shares at $15 each for gross proceeds of $225-million. In its first day of trading on June 18, the stock jumped $4.45, or 29%, to...

June 18, 2021

Developments

Versant, RA Capital launch LENZ Therapeutics in $47-million series A

A $47-million series A financing from Versant Ventures and RA Capital Management launched LENZ Therapeutics, with a lead late-stage clinical program for presbyopia. Proceeds from the financing will be used to progress...

June 17, 2021

Developments

Clearside Biomedical posts positive safety results in Phase 1/2a wet AMD study

Clearside Biomedical (NASDAQ:CLSD) reported positive safety results from Cohort 1 of OASIS, its ongoing Phase 1/2a clinical trial of CLS-AX, an axitinib injectable suspension, which is administered by suprachoroidal...

June 15, 2021

Developments

Lucid Psycheceuticals in pact with UHN to develop neurodegenerative therapeutics

Lucid Psycheceuticals inked a world-wide license agreement with Toronto’s University Health Network (UHN), Canada’s top research hospital, granting Lucid exclusive rights to novel compounds for therapeutic applications...

June 14, 2021

Developments

Lineage reports additional cases of retinal tissue restoration in dry AMD with OpRegen

Lineage Cell Therapeutics (NASDAQ, TASE:LCTX) reported that restoration of retinal tissue was observed in two additional patients enrolled in the company’s Phase 1/2a study of its lead product candidate, OpRegen. ...

June 1, 2021

Developments

Ripple Therapeutics polymer-free drug delivery published in Nature Communications

An article describing Ripple Therapeutics’ Epidel technology platform entitled, “Polymer-Free Corticosteroid Dimer Implants for Controlled and Sustained Drug Delivery,” was recently published in the peer-reviewed...

June 1, 2021

Developments

Seelos receives European orphan drug designation for SLS-005 in ALS

Seelos Therapeutics (NASDAQ:SEEL) received European orphan drug designation for SLS-005 in amyotrophic lateral sclerosis (ALS) from the European Medicines Agency Committee for Orphan Medicinal Products. Under orphan...

May 27, 2021

Developments

KA Imaging in U.S. distribution pact with Alpha Imaging

KA Imaging signed a U.S. distribution agreement with Ohio-based Alpha Imaging for its Reveal 35C portable dual-energy X-ray detector. Alpha Imaging is one of the largest distributors of medical imaging equipment in the...

May 26, 2021

Markets

Cantor starts Chemomab Therapeutics at OW; PT $45

Cantor Fitzgerald initiated coverage of Chemomab Therapeutics (NASDAQ:CMMB) with an “overweight” rating and $45 price target. The stock closed at $16.07 on May 25. Chemomab is a clinical-stage biotech company focusing...

May 26, 2021

Executive Moves

Doug Kleinberg joins BTIG healthcare investment banking

Doug Kleinberg Doug Kleinberg has joined BTIG’s healthcare investment banking unit as a managing director to focus on investment banking opportunities for corporate clients across biotech, biopharma and pharma. Mr...

May 24, 2021

Author - Melane Sampson

atai Life Sciences prices $225-million IPO

Versant, RA Capital launch LENZ Therapeutics in $47-million series A

Clearside Biomedical posts positive safety results in Phase 1/2a wet AMD study

Lucid Psycheceuticals in pact with UHN to develop neurodegenerative therapeutics

Lineage reports additional cases of retinal tissue restoration in dry AMD with OpRegen

Ripple Therapeutics polymer-free drug delivery published in Nature Communications

Seelos receives European orphan drug designation for SLS-005 in ALS

KA Imaging in U.S. distribution pact with Alpha Imaging

Cantor starts Chemomab Therapeutics at OW; PT $45

Doug Kleinberg joins BTIG healthcare investment banking

Subscribe